These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 29958025)

  • 1. Duration of Catheter Use in Patients with Diabetes Using Continuous Subcutaneous Insulin Infusion: A Review.
    Bonato L; Taleb N; Gingras V; Messier V; Gobeil F; Ménard J; Ardilouze JL; Rabasa-Lhoret R
    Diabetes Technol Ther; 2018 Jul; 20(7):506-515. PubMed ID: 29958025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perceptions and experiences of adult patients with type 1 diabetes using continuous subcutaneous insulin infusion therapy: Results of an online survey.
    Taleb N; Messier V; Ott-Braschi S; Ardilouze JL; Rabasa-Lhoret R
    Diabetes Res Clin Pract; 2018 Oct; 144():42-50. PubMed ID: 30077691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detailed Analysis of Insulin Absorption Variability and the Tissue Response to Continuous Subcutaneous Insulin Infusion Catheter Implantation in Swine.
    Hauzenberger JR; Hipszer BR; Loeum C; McCue PA; DeStefano M; Torjman MC; Kaner MT; Dinesen AR; Chervoneva I; Pieber TR; Joseph JI
    Diabetes Technol Ther; 2017 Nov; 19(11):641-650. PubMed ID: 28981324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of infusion rate and indwelling time on tissue resistance pressure in small-volume subcutaneous infusion like in continuous subcutaneous insulin infusion.
    Patte C; Pleus S; Wiegel C; Schiltges G; Jendrike N; Haug C; Freckmann G
    Diabetes Technol Ther; 2013 Apr; 15(4):289-94. PubMed ID: 23427865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin pump risks and benefits: a clinical appraisal of pump safety standards, adverse event reporting and research needs. A joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group.
    Heinemann L; Fleming GA; Petrie JR; Holl RW; Bergenstal RM; Peters AL
    Diabetologia; 2015 May; 58(5):862-70. PubMed ID: 25784563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency of dermatological side effects of continuous subcutaneous insulin infusion in children and adolescents with type 1 diabetes.
    Binder E; Lange O; Edlinger M; Meraner D; Abt D; Moser C; Steichen E; Hofer SE
    Exp Clin Endocrinol Diabetes; 2015 Apr; 123(4):260-4. PubMed ID: 25607337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous subcutaneous insulin infusion therapy: A primer on insulin pumps.
    Potti LG; Haines ST
    J Am Pharm Assoc (2003); 2009; 49(1):e1-13; quiz e14-7. PubMed ID: 19196588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pilot study for assessment of optimal frequency for changing catheters in insulin pump therapy-trouble starts on day 3.
    Schmid V; Hohberg C; Borchert M; Forst T; Pfützner A
    J Diabetes Sci Technol; 2010 Jul; 4(4):976-82. PubMed ID: 20663464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin pump risks and benefits: a clinical appraisal of pump safety standards, adverse event reporting, and research needs: a joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group.
    Heinemann L; Fleming GA; Petrie JR; Holl RW; Bergenstal RM; Peters AL
    Diabetes Care; 2015 Apr; 38(4):716-22. PubMed ID: 25776138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using Insulin Infusion Sets in CSII for Longer Than the Recommended Usage Time Leads to a High Risk for Adverse Events: Results From a Prospective Randomized Crossover Study.
    Pfützner A; Sachsenheimer D; Grenningloh M; Heschel M; Walther-Johannesen L; Gharabli R; Klonoff D
    J Diabetes Sci Technol; 2015 Sep; 9(6):1292-8. PubMed ID: 26341262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Position statement: Continuous subcutaneous insulin infusion in very young children with type 1 diabetes.
    Eugster EA; Francis G;
    Pediatrics; 2006 Oct; 118(4):e1244-9. PubMed ID: 17015512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lower rate of initial failures and reduced occurrence of adverse events with a new catheter model for continuous subcutaneous insulin infusion: prospective, two-period, observational, multicenter study.
    Renard E; Guerci B; Leguerrier AM; Boizel R;
    Diabetes Technol Ther; 2010 Oct; 12(10):769-73. PubMed ID: 20809682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue Response to Subcutaneous Infusion Catheter.
    Zhang E; Cao Z
    J Diabetes Sci Technol; 2020 Mar; 14(2):226-232. PubMed ID: 30931603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The use of continuous subcutaneous insulin infusion (CSII) with personal insulin pumps in the treatment of children and adolescents with diabetes type 1].
    Jarosz-Chobot P
    Wiad Lek; 2004; 57(5-6):263-6. PubMed ID: 15518073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term health economic benefits of sensor-augmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: a U.K. perspective.
    Roze S; Smith-Palmer J; Valentine WJ; Cook M; Jethwa M; de Portu S; Pickup JC
    J Med Econ; 2016; 19(3):236-42. PubMed ID: 26510389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Present role of continuous subcutaneous insulin infusion (CSII) by insulin pump in the treatment of diabetes mellitus].
    Pfützner A; Berger S; Spinas G
    Schweiz Med Wochenschr; 2000 Dec; 130(48):1854-61. PubMed ID: 11132530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Indications for the use of continuous subcutaneous insulin infusion in pediatric patients with type 1 diabetes mellitus].
    Espejel-Huerta D; Antillón-Ferreira CA; Iglesias-Leboreiro J; Bernárdez-Zapata I; Martínez-Ramos Méndez A; Rendón-Macías ME
    Rev Med Inst Mex Seguro Soc; 2016; 54(1):64-9. PubMed ID: 26820201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin Distribution in Human Adipose Tissue via a Novel Insulin Infusion Catheter.
    Altendorfer-Kroath T; Schwingenschuh S; Schøndorff PK; Heschel M; Sinner F; Birngruber T
    Diabetes Technol Ther; 2019 Dec; 21(12):740-744. PubMed ID: 31448965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fields of application of continuous subcutaneous insulin infusion in the treatment of diabetes and implications in the use of rapid-acting insulin analogues.
    Pitocco D; Rizzi A; Scavone G; Tanese L; Zaccardi F; Manto A; Ghirlanda G
    Minerva Endocrinol; 2013 Sep; 38(3):321-8. PubMed ID: 24126552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Why pumps? Continuous subcutaneous insulin infusion for children and adolescents with type 1 diabetes.
    Weintrob N; Shalitin S; Phillip M
    Isr Med Assoc J; 2004 May; 6(5):271-5. PubMed ID: 15151365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.